Last reviewed · How we verify
NCT06794125: PREVENT-LUNG
An Evaluation of Dose-escalation for Intrathoracic Tumours
NA trial testing Hypofractionated Radiation Therapy in Lung Cancers in 141 participants. Currently enrolling.
1 March 2029
Quick facts
| Lead sponsor | Chris Goodman |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 141 |
| Start date | 3 September 2025 |
| Primary completion | 1 March 2029 |
| Estimated completion | 1 March 2029 |
| Sites | 3 locations across Canada |
Drugs / interventions tested
- Hypofractionated Radiation Therapy — full drug profile →
- Radiation Therapy — full drug profile →
Conditions studied
- Lung Cancers — all drugs for Lung Cancers →
Sponsor
Chris Goodman
Who can join
18 and older, any sex, with Lung Cancers. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a pragmatic trial with patients randomized between standard of care palliative thoracic radiation therapy (RT) vs. hypofractionated, dose-escalated, esophageal-sparing (HD-ES) intensity modulated radiation therapy (IMRT). The investigators hypothesize that the use of advanced radiation planning techniques to optimize dose to esophagus will permit the safe delivery of a modestly dose-escalated five-fraction course of palliative radiation to intrathoracic malignancies. This approach aims to deliver higher biologically effective doses while improving toxicity when compared to conventional approaches with the goal of prolonging high-quality overall survival.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06794125
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Hypofractionated Radiation Therapy
Trials testing the same drug.
- NCT07276360 — Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda · Phase 2 · recruiting
- NCT07188532 — Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial · NA · recruiting
- NCT07097142 — Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemothera · Phase 3 · recruiting
- NCT07052669 — Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC · Phase 3 · recruiting
- NCT06635980 — Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer · Phase 2 · recruiting
Other recruiting trials for Lung Cancers
Currently open trials in the same condition.
- NCT06926075 — Early Phase Study of KESONOTIDE™in Participants With Solid Tumours · Phase 1, PHASE2 · recruiting
- NCT07057648 — Shape-Sensing Robotic-Assisted Bronchoscopy for Diagnosis of Peripheral Pulmonary Nodules in Korea · recruiting
- NCT06926140 — Acupuncture Combined With PD-1/PD-L1 Inhibitors for Advanced Lung Cancer · NA · recruiting
- NCT07064395 — Bright Light Therapy on Sleep Health in Lung Cancer Patients · NA · recruiting
- NCT06942143 — An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06794125 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chris Goodman
- Last refreshed: 4 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06794125.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing